Ajanta Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
NiveshIQ
NSE: AJANTPHARM · Healthcare
Ajanta Pharmaceuticals Ltd.
₹3,396.30▼ ₹112.50 (-3.21%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AJANTPHARM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Ajanta Pharmaceuticals Ltd.
Ajanta Pharma Limited is a specialty pharmaceutical formulation company headquartered in Mumbai, offering a broad portfolio of chronic and acute therapies across cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company’s revenue drivers include branded generic tablets, capsules, eye drops, injectables, and inhalers, with a strong presence in India, Africa, Asia, and the United States. In Q2 FY27, Ajanta Pharma reported a 33% surge in revenue to ₹6,239 crore and a 49% year‑on‑year rise in net profit to ₹1,263 crore, reflecting robust pricing power and efficient cost management. Competitive positioning is bolstered by a diversified product mix, a robust R&D pipeline, and a global distribution network that mitigates regional market risks. Recent develo
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹4,209 Cr +12.45% | ₹4,648 Cr +10.44% | ₹5,453 Cr +17.31% |
| EBITDA Margin | 27.85% | 27.10% | 25.58% |
| Net Profit | ₹816.98 Cr +38.95% | ₹920.39 Cr +12.66% | ₹1,056 Cr +14.73% |
| EPS | ₹64.82 | ₹73.56 | ₹84.53 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Buy Ajanta Pharma; target of Rs 4250: Prabhudas Lilladher
Ajanta Pharma NSE:AJANTPHARM Q2 FY27 Newspaper Results Filing
🔒
+ 3 more stories about Ajanta Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹1, 794 Cr, PAT ₹388 Cr, EPS ₹31.07, EBITDA margin 30.5%. Growth context: revenue YoY +32.5%, PAT YoY +49.2%, revenue QoQ +10.3%, PAT QoQ +17.6%.
Management highlights product launches, regulatory approvals, and a shift in therapy mix as the main near‑term growth dr...
FY26 (last completed FY): revenue ₹5, 453 Cr, PAT ₹1, 056 Cr, EBITDA margin 25.6%, EPS ₹84.53. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AJANTPHARM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AJANTPHARM alongside your other holdings
Unlock full AJANTPHARM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Ajanta Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Ajanta Pharmaceuticals Ltd. (AJANTPHARM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Ajanta Pharmaceuticals Ltd.?
Ajanta Pharmaceuticals Ltd. operates in the Healthcare sector with a market capitalisation of ₹3,791,796.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.